TW202328458A - 癌症檢測之血漿ｄｎａ突變分析 - Google Patents

癌症檢測之血漿ｄｎａ突變分析 Download PDF

Info

Publication number
TW202328458A
TW202328458A TW111143054A TW111143054A TW202328458A TW 202328458 A TW202328458 A TW 202328458A TW 111143054 A TW111143054 A TW 111143054A TW 111143054 A TW111143054 A TW 111143054A TW 202328458 A TW202328458 A TW 202328458A
Authority
TW
Taiwan
Prior art keywords
tumor
mutations
dna
cancer
plasma
Prior art date
Application number
TW111143054A
Other languages
English (en)
Chinese (zh)
Inventor
煜明 盧
慧君 趙
君賜 陳
江培勇
Original Assignee
香港中文大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港中文大學 filed Critical 香港中文大學
Publication of TW202328458A publication Critical patent/TW202328458A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C12Q2539/107—Representational Difference Analysis [RDA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW111143054A 2012-06-21 2013-06-20 癌症檢測之血漿ｄｎａ突變分析 TW202328458A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261662878P 2012-06-21 2012-06-21
US61/662,878 2012-06-21
US201261682725P 2012-08-13 2012-08-13
US61/682,725 2012-08-13
US201261695795P 2012-08-31 2012-08-31
US61/695,795 2012-08-31
US201261711172P 2012-10-08 2012-10-08
US61/711,172 2012-10-08
US13/801,748 2013-03-13
US13/801,748 US11261494B2 (en) 2012-06-21 2013-03-13 Method of measuring a fractional concentration of tumor DNA

Publications (1)

Publication Number Publication Date
TW202328458A true TW202328458A (zh) 2023-07-16

Family

ID=52274459

Family Applications (4)

Application Number Title Priority Date Filing Date
TW102122036A TWI636255B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿ｄｎａ突變分析
TW107128593A TWI803505B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿dna突變分析
TW109127987A TWI786428B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿dna突變分析
TW111143054A TW202328458A (zh) 2012-06-21 2013-06-20 癌症檢測之血漿ｄｎａ突變分析

Family Applications Before (3)

Application Number Title Priority Date Filing Date
TW102122036A TWI636255B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿ｄｎａ突變分析
TW107128593A TWI803505B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿dna突變分析
TW109127987A TWI786428B (zh) 2012-06-21 2013-06-20 癌症檢測之血漿dna突變分析

Country Status (18)

Country Link
US (3) US11261494B2 (enExample)
EP (4) EP4512907A3 (enExample)
JP (4) JP6371280B2 (enExample)
KR (7) KR102375645B1 (enExample)
CN (3) CN113151474A (enExample)
AU (4) AU2013278994C1 (enExample)
CA (2) CA3080937A1 (enExample)
DK (2) DK3456843T3 (enExample)
EA (2) EA202092900A3 (enExample)
ES (2) ES2894479T3 (enExample)
HU (1) HUE056915T2 (enExample)
IL (5) IL311127B2 (enExample)
MX (3) MX360264B (enExample)
PT (1) PT3456843T (enExample)
SG (2) SG11201408113QA (enExample)
TW (4) TWI636255B (enExample)
WO (1) WO2013190441A2 (enExample)
ZA (1) ZA201409281B (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892736A1 (en) 2007-07-23 2021-10-13 The Chinese University of Hong Kong Determining a nucleic acid sequence imbalance
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
IN2013MN00522A (enExample) 2010-09-24 2015-05-29 Univ Leland Stanford Junior
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US20130309666A1 (en) 2013-01-25 2013-11-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3421613B1 (en) * 2013-03-15 2020-08-19 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2014144092A1 (en) 2013-03-15 2014-09-18 Nugen Technologies, Inc. Sequential sequencing
CN105849264B (zh) 2013-11-13 2019-09-27 纽亘技术公司 用于鉴别重复测序读数的组合物和方法
SG11201604923XA (en) 2013-12-28 2016-07-28 Guardant Health Inc Methods and systems for detecting genetic variants
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US12492429B2 (en) * 2014-04-21 2025-12-09 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
TWI813141B (zh) 2014-07-18 2023-08-21 香港中文大學 Ｄｎａ混合物中之組織甲基化模式分析
CN107002122B (zh) * 2014-07-25 2023-09-19 华盛顿大学 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法
JP6803327B2 (ja) 2014-08-06 2020-12-23 ニューゲン テクノロジーズ， インコーポレイテッド 標的化されたシークエンシングからのデジタル測定値
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
WO2016020710A1 (en) * 2014-08-07 2016-02-11 Pharmassist Ltd Method of determining pik3ca mutational status in a sample
EP3191628B1 (en) 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
CA2967447C (en) * 2014-12-05 2025-07-08 Foundation Medicine, Inc. MULTIGEN ANALYSIS OF TUMOR SAMPLES
WO2016094853A1 (en) 2014-12-12 2016-06-16 Verinata Health, Inc. Using cell-free dna fragment size to determine copy number variations
ES2828279T3 (es) * 2014-12-31 2021-05-25 Guardant Health Inc Detección y tratamiento de enfermedades que muestran heterogeneidad celular de enfermedad y sistemas y métodos para comunicar los resultados de las pruebas
US10364467B2 (en) * 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
CA2976303A1 (en) * 2015-02-10 2016-08-18 The Chinese University Of Hong Kong Detecting mutations for cancer screening and fetal analysis
CN119214645A (zh) * 2015-05-01 2024-12-31 夸登特健康公司 诊断方法
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
CN104894268B (zh) * 2015-06-05 2018-02-09 上海美吉生物医药科技有限公司 定量样本中源自细胞凋亡的dna浓度的方法及其应用
CN107849556A (zh) * 2015-07-01 2018-03-27 学校法人庆应义塾 癌组织的异质性标记物及其使用
JP2017016665A (ja) * 2015-07-03 2017-01-19 国立大学法人東北大学 配列のデータからの変異情報の選択方法、システム、及び、コンピュータプログラム
EP3325663B1 (en) 2015-07-20 2020-08-19 The Chinese University Of Hong Kong Methylation pattern analysis of haplotypes in tissues in dna mixture
EP3325664B1 (en) 2015-07-23 2021-12-29 The Chinese University Of Hong Kong Analysis of fragmentation patterns of cell-free dna
HK1248286A1 (zh) * 2015-08-12 2018-10-12 The Chinese University Of Hong Kong 血浆dna的单分子测序
AU2016310501B2 (en) 2015-08-25 2019-11-07 Nantomics, Llc Systems and methods for genetic analysis of metastases
CN108603228B (zh) 2015-12-17 2023-09-01 夸登特健康公司 通过分析无细胞dna确定肿瘤基因拷贝数的方法
CN109072309B (zh) * 2016-02-02 2023-05-16 夸登特健康公司 癌症进化检测和诊断
US10095831B2 (en) 2016-02-03 2018-10-09 Verinata Health, Inc. Using cell-free DNA fragment size to determine copy number variations
KR101810528B1 (ko) * 2016-03-29 2017-12-21 한국과학기술원 단백질을 변화시키지 않는 암 돌연변이의 기능적 recurrence를 구하는 방법 및 장치
EP4488686A3 (en) * 2016-04-14 2025-04-30 Guardant Health, Inc. Methods for early detection of cancer
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
WO2017191076A1 (en) 2016-05-01 2017-11-09 Genome Research Limited Method of characterising a dna sample
GB2555765A (en) 2016-05-01 2018-05-16 Genome Res Ltd Method of detecting a mutational signature in a sample
CN105969856B (zh) * 2016-05-13 2019-11-12 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测方法
CN105969656B (zh) * 2016-05-13 2019-09-10 万康源(天津)基因科技有限公司 一种单细胞外显子测序肿瘤体细胞突变检测及分析平台
CN106355045B (zh) * 2016-08-30 2019-03-15 天津诺禾致源生物信息科技有限公司 一种基于扩增子二代测序小片段插入缺失检测的方法及装置
JP6560465B1 (ja) * 2016-09-30 2019-08-21 ガーダント ヘルス， インコーポレイテッド 無細胞核酸の多重解像度分析のための方法
SG11201903509QA (en) 2016-10-24 2019-05-30 Univ Hong Kong Chinese Methods and systems for tumor detection
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CN108473975A (zh) * 2016-11-17 2018-08-31 领星生物科技（上海）有限公司 检测肿瘤发展的系统和方法
IL315032A (en) 2016-11-30 2024-10-01 Univ Hong Kong Chinese Analysis of cell-free dna in urine and other samples
WO2018106884A1 (en) * 2016-12-08 2018-06-14 Life Technologies Corporation Methods for detecting mutation load from a tumor sample
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
MY197535A (en) 2017-01-25 2023-06-21 Univ Hong Kong Chinese Diagnostic applications using nucleic acid fragments
US12492430B2 (en) 2017-04-11 2025-12-09 Tecan Genomics, Inc. Library quantitation and qualification
US11342047B2 (en) * 2017-04-21 2022-05-24 Illumina, Inc. Using cell-free DNA fragment size to detect tumor-associated variant
WO2018213498A1 (en) * 2017-05-16 2018-11-22 Guardant Health, Inc. Identification of somatic or germline origin for cell-free dna
KR102145417B1 (ko) * 2017-05-24 2020-08-19 지니너스 주식회사 무세포 핵산으로부터 수득된 서열 분석 데이터에 대한 배경 대립인자의 빈도 분포를 생성하는 방법 및 이를 이용하여 무세포 핵산으로부터 변이를 검출하는 방법
ES2959360T3 (es) 2017-07-26 2024-02-23 Univ Hong Kong Chinese Mejora del cribado del cáncer mediante ácidos nucleicos víricos acelulares
US20210125683A1 (en) * 2017-09-15 2021-04-29 The Regents Of The University Of California Detecting somatic single nucleotide variants from cell-free nucleic acid with application to minimal residual disease monitoring
SG11202002381TA (en) * 2017-09-20 2020-04-29 Guardant Health Inc Methods and systems for differentiating somatic and germline variants
US20200265922A1 (en) * 2017-10-10 2020-08-20 Nantomics, Llc Comprehensive Genomic Transcriptomic Tumor-Normal Gene Panel Analysis For Enhanced Precision In Patients With Cancer
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
WO2019090156A1 (en) * 2017-11-03 2019-05-09 Guardant Health, Inc. Normalizing tumor mutation burden
ES3040876T3 (en) * 2017-11-30 2025-11-05 Illumina Inc Validation methods and systems for sequence variant calls
CA3085933A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
US20190249229A1 (en) * 2018-02-12 2019-08-15 Nant Holdings Ip, Llc Bam signatures from liquid and solid tumors and uses therefor
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
EP3781709A4 (en) * 2018-04-16 2022-11-30 Grail, LLC Systems and methods for determining tumor fraction in cell-free nucleic acid
AU2019277698A1 (en) 2018-06-01 2020-11-19 Grail, Llc Convolutional neural network systems and methods for data classification
WO2019236478A1 (en) * 2018-06-04 2019-12-12 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free nucleic acids
KR20210035167A (ko) 2018-06-11 2021-03-31 파운데이션 메디신 인코포레이티드 게놈 변경을 평가하기 위한 조성물 및 방법
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
AU2019310041B2 (en) 2018-07-23 2025-11-20 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
IL279435B1 (en) 2018-11-01 2025-10-01 Illumina Inc Methods and compositions for somatic variant detection
JP7499239B2 (ja) * 2018-11-13 2024-06-13 ミリアド・ジェネティックス・インコーポレイテッド 体細胞変異のための方法およびシステム、ならびにそれらの使用
US11581062B2 (en) 2018-12-10 2023-02-14 Grail, Llc Systems and methods for classifying patients with respect to multiple cancer classes
DK3899018T3 (da) 2018-12-19 2024-01-08 Univ Hong Kong Chinese Cellefri DNA-endeegenskaber
EP3899956A4 (en) * 2018-12-21 2022-11-23 Grail, LLC SYSTEMS AND METHODS FOR USING FRAGMENT LENGTH AS A PREDICTOR OF CANCER
CN109616198A (zh) * 2018-12-28 2019-04-12 陈洪亮 仅用于肝癌单一癌种筛查的特异甲基化检测位点组合的选取方法
CN109686414A (zh) * 2018-12-28 2019-04-26 陈洪亮 仅用于肝癌筛查的特异甲基化检测位点组合的选取方法
CN109817279B (zh) * 2019-01-18 2022-11-04 臻悦生物科技江苏有限公司 肿瘤突变负荷的检测方法、装置、存储介质及处理器
KR102381252B1 (ko) * 2019-02-19 2022-04-01 주식회사 녹십자지놈 혈중 무세포 dna 기반 간암 치료 예후예측 방법
CN109841265B (zh) * 2019-02-22 2021-09-21 清华大学 使用片段化模式确定血浆游离核酸分子组织来源的方法和系统及应用
CN109920480B (zh) * 2019-03-14 2020-02-21 深圳市海普洛斯生物科技有限公司 一种校正高通量测序数据的方法和装置
CN111755075B (zh) * 2019-03-28 2023-09-29 深圳华大生命科学研究院 对免疫组库高通量测序样本间序列污染进行过滤的方法
US12497662B2 (en) 2019-04-16 2025-12-16 Grail, Inc. Systems and methods for tumor fraction estimation from small variants
EP3963105A4 (en) 2019-05-03 2023-12-20 Ultima Genomics, Inc. METHOD FOR DETECTING NUCLEIC ACID VARIANTS
US12437839B2 (en) 2019-05-03 2025-10-07 Ultima Genomics, Inc. Methods for detecting nucleic acid variants
WO2020236630A1 (en) * 2019-05-17 2020-11-26 Ultima Genomics, Inc. Methods and systems for detecting residual disease
KR20220011140A (ko) * 2019-05-20 2022-01-27 파운데이션 메디신 인코포레이티드 종양 분획 평가를 위한 시스템 및 방법
CN111223525A (zh) * 2020-01-07 2020-06-02 广州基迪奥生物科技有限公司 一种肿瘤外显子测序数据分析方法
CN113275053A (zh) 2020-02-03 2021-08-20 帝肯基因组学公司 试剂存储系统
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
JP7022861B1 (ja) * 2021-06-25 2022-02-18 株式会社日立パワーソリューションズ アレイ型超音波送受信装置
WO2023278524A1 (en) * 2021-06-30 2023-01-05 Memorial Sloan-Kettering Cancer Center Detection of somatic mutational signatures from whole genome sequencing of cell-free dna
CN114242172B (zh) * 2021-07-12 2025-04-25 广州燃石医学检验所有限公司 基于血液测序的肿瘤内异质性的评估方法及其用于预测免疫疗法的应答
KR20230085239A (ko) * 2021-12-06 2023-06-14 주식회사 지씨지놈 혈중 무세포 dna 기반 유방암 치료 예후예측 방법
CN115064212B (zh) * 2022-06-24 2023-03-14 哈尔滨星云生物信息技术开发有限公司 基于wgs数据的预设区域人群肿瘤特异突变识别方法
WO2024003936A1 (en) 2022-06-29 2024-01-04 Raman Govindarajan Method for detecting cancer susceptibility, early detection and predicting cancer behaviour
KR20240051739A (ko) * 2022-10-13 2024-04-22 인하대학교 산학협력단 cfDNA의 구조 변이 서열 검출을 통한 미세잔존질환 진단 방법
CN117012274B (zh) * 2023-10-07 2024-01-16 北京智因东方转化医学研究中心有限公司 基于高通量测序识别基因缺失的装置

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2028190A1 (en) 1999-04-02 2009-02-25 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
US20030211522A1 (en) 2002-01-18 2003-11-13 Landes Gregory M. Methods for fetal DNA detection and allele quantitation
EP1509619B1 (en) 2002-05-10 2012-04-04 City of Hope Pyrophosphorolysis activated polymerization (pap)
US7704687B2 (en) 2002-11-15 2010-04-27 The Johns Hopkins University Digital karyotyping
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
PL201608B1 (pl) 2003-06-13 2009-04-30 Cezary Cybulski Sposób i zestaw do wykrywania wysokiej genetycznie uwarunkowanej predyspozycji do raka prostaty oraz zastosowanie zmiany germinalnej w obrębie genu NBS1
ATE435301T1 (de) 2003-10-16 2009-07-15 Sequenom Inc Nicht invasiver nachweis fötaler genetischer merkmale
WO2005108621A1 (en) 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
CN101137760B (zh) * 2005-03-18 2011-01-26 香港中文大学 检测染色体非整倍性的方法
US20070122823A1 (en) 2005-09-01 2007-05-31 Bianchi Diana W Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis
ES2739484T3 (es) 2006-02-02 2020-01-31 Univ Leland Stanford Junior Prueba genética fetal no invasiva mediante análisis digital
CA2647793C (en) 2006-02-28 2016-07-05 University Of Louisville Research Foundation Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
EA010571B1 (ru) 2006-08-15 2008-10-30 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Способ диагностики немелкоклеточного рака легких и набор для его осуществления
AU2008256219B2 (en) 2007-05-25 2014-06-05 Decode Genetics Ehf. Genetic variants on Chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP3892736A1 (en) 2007-07-23 2021-10-13 The Chinese University of Hong Kong Determining a nucleic acid sequence imbalance
US20090053719A1 (en) 2007-08-03 2009-02-26 The Chinese University Of Hong Kong Analysis of nucleic acids by digital pcr
WO2009051842A2 (en) * 2007-10-18 2009-04-23 The Johns Hopkins University Detection of cancer by measuring genomic copy number and strand length in cell-free dna
US20100041048A1 (en) 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP2952589B1 (en) * 2008-09-20 2018-02-14 The Board of Trustees of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8835110B2 (en) * 2008-11-04 2014-09-16 The Johns Hopkins University DNA integrity assay (DIA) for cancer diagnostics, using confocal fluorescence spectroscopy
US20100136560A1 (en) 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
WO2010091046A2 (en) * 2009-02-03 2010-08-12 President & Fellows Of Harvard College Systems and methods for high throughput, high fidelity, single molecule nucleic acid sequencing using time multiplexed excitation
WO2010112316A1 (en) 2009-03-31 2010-10-07 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Method for diagnosis of cancer and monitoring of cancer treatments
US20120208711A1 (en) 2009-10-02 2012-08-16 Centre For Addiction And Mental Health Method for Analysis of DNA Methylation Profiles of Cell-Free Circulating DNA in Bodily Fluids
WO2011053790A2 (en) 2009-10-30 2011-05-05 Fluidigm Corporation Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis
CN102770558B (zh) 2009-11-05 2016-04-06 香港中文大学 由母本生物样品进行胎儿基因组的分析
CA2780016C (en) 2009-11-06 2017-09-19 The Chinese University Of Hong Kong Size-based genomic analysis
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
CA2786564A1 (en) 2010-01-19 2011-07-28 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic dna by whole genome sequencing
AU2010343276B2 (en) 2010-01-19 2015-05-28 Verinata Health, Inc. Methods for determining fraction of fetal nucleic acid in maternal samples
EP2536854B1 (en) 2010-02-18 2017-07-19 The Johns Hopkins University Personalized tumor biomarkers
EP2426217A1 (en) * 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
KR102040307B1 (ko) 2010-11-30 2019-11-27 더 차이니즈 유니버시티 오브 홍콩 암과 연관된 유전적 또는 분자적 이상들의 검출
GB2485635B (en) 2011-07-26 2012-11-28 Verinata Health Inc Method for determining the presence or absence of different aneuploidies in a sample
AU2012318371B2 (en) 2011-10-06 2018-03-22 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2013060762A1 (en) * 2011-10-25 2013-05-02 Roche Diagnostics Gmbh Method for diagnosing a disease based on plasma-dna distribution
US10214775B2 (en) 2011-12-07 2019-02-26 Chronix Biomedical Prostate cancer associated circulating nucleic acid biomarkers
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
CA2867293C (en) 2012-03-13 2020-09-01 Abhijit Ajit PATEL Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing
US11261494B2 (en) 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
KR102393608B1 (ko) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법
US20160186267A1 (en) 2013-02-21 2016-06-30 Toma Biosciences, Inc. Methods, compositions, and kits for nucleic acid analysis
EP3409791B1 (en) 2013-03-15 2021-06-30 Verinata Health, Inc. Generating cell-free dna libraries directly from blood
US10174375B2 (en) 2013-09-20 2019-01-08 The Chinese University Of Hong Kong Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
CN107002122B (zh) 2014-07-25 2023-09-19 华盛顿大学 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法

Also Published As

Publication number Publication date
CN107779506B (zh) 2022-07-15
IL298810B1 (en) 2024-04-01
EP3456843B1 (en) 2021-07-28
MX2023001154A (es) 2023-02-22
HK1204013A1 (en) 2015-11-06
SG11201408113QA (en) 2015-01-29
KR102375645B1 (ko) 2022-03-17
ES2687847T3 (es) 2018-10-29
AU2013278994A1 (en) 2015-01-29
JP2021191280A (ja) 2021-12-16
EP3456843A1 (en) 2019-03-20
IL298810B2 (en) 2024-08-01
EP3919627C0 (en) 2024-10-30
AU2020200122B2 (en) 2022-05-19
EP4512907A2 (en) 2025-02-26
IL311127A (en) 2024-04-01
KR101884909B1 (ko) 2018-08-02
PT3456843T (pt) 2021-10-26
KR20240049635A (ko) 2024-04-16
JP6930948B2 (ja) 2021-09-01
ZA201409281B (en) 2017-08-30
IL298810A (en) 2023-02-01
US11261494B2 (en) 2022-03-01
KR20230052998A (ko) 2023-04-20
AU2017204558B2 (en) 2019-10-10
IL235967B (en) 2019-09-26
EP2864501A4 (en) 2016-03-16
AU2013278994B2 (en) 2017-04-06
HUE056915T2 (hu) 2022-03-28
KR102521842B1 (ko) 2023-04-14
CN113151474A (zh) 2021-07-23
WO2013190441A3 (en) 2014-02-27
EP3919627B1 (en) 2024-10-30
CA2876327C (en) 2020-09-29
KR20220038181A (ko) 2022-03-25
TW201403066A (zh) 2014-01-16
HK1246830A1 (zh) 2018-09-14
CN104662168A (zh) 2015-05-27
KR20200035507A (ko) 2020-04-03
JP2018191640A (ja) 2018-12-06
EA037292B1 (ru) 2021-03-05
IL268645A (en) 2019-10-31
CA3080937A1 (en) 2013-12-27
MX2014016058A (es) 2015-04-10
KR102096611B1 (ko) 2020-04-02
EA201500027A1 (ru) 2015-05-29
WO2013190441A2 (en) 2013-12-27
KR102720785B1 (ko) 2024-10-22
IL278867B1 (en) 2023-01-01
US20190264291A1 (en) 2019-08-29
EA202092900A2 (ru) 2021-03-31
MX360264B (es) 2018-10-26
EP2864501B1 (en) 2018-08-08
MX2018013085A (es) 2021-11-16
IL235967A0 (en) 2015-01-29
US20180202003A1 (en) 2018-07-19
TW202122796A (zh) 2021-06-16
IL278867B2 (en) 2023-05-01
CA2876327A1 (en) 2013-12-27
EA202092900A3 (ru) 2021-06-30
KR102656030B1 (ko) 2024-04-08
SG10201808217WA (en) 2018-10-30
HK1205533A1 (en) 2015-12-18
TWI636255B (zh) 2018-09-21
TWI786428B (zh) 2022-12-11
EP4512907A3 (en) 2025-05-14
AU2022209294A1 (en) 2022-08-25
KR20150032708A (ko) 2015-03-27
JP7408161B2 (ja) 2024-01-05
JP2015527057A (ja) 2015-09-17
EP2864501A2 (en) 2015-04-29
TWI803505B (zh) 2023-06-01
KR20180088922A (ko) 2018-08-07
EP3919627A1 (en) 2021-12-08
AU2017204558A1 (en) 2017-07-27
IL311127B2 (en) 2025-03-01
IL311127B1 (en) 2024-11-01
AU2013278994C1 (en) 2019-12-12
DK3456843T3 (da) 2021-10-25
KR102237923B1 (ko) 2021-04-08
DK2864501T3 (en) 2018-11-05
TW201920952A (zh) 2019-06-01
JP6371280B2 (ja) 2018-08-08
ES2894479T3 (es) 2022-02-14
CN107779506A (zh) 2018-03-09
IL278867A (en) 2021-01-31
CN104662168B (zh) 2017-12-05
KR20210040464A (ko) 2021-04-13
US20140100121A1 (en) 2014-04-10
JP2024026360A (ja) 2024-02-28
AU2020200122A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
TWI786428B (zh) 癌症檢測之血漿dna突變分析
HK40065246B (en) Mutational analysis of plasma dna for cancer detection
HK40056499A (en) Mutational analysis of plasma dna for cancer detection
HK40065246A (en) Mutational analysis of plasma dna for cancer detection
HK40006067B (en) Mutational analysis of plasma dna for cancer detection
HK40006067A (en) Mutational analysis of plasma dna for cancer detection
HK1246830B (en) Mutational analysis of plasma dna for cancer detection
HK1205533B (en) Mutational analysis of plasma dna for cancer detection
EA047100B1 (ru) Мутационный анализ днк в плазме для детектирования рака
HK1204013B (en) Mutational analysis of plasma dna for cancer detection
EA042093B1 (ru) Мутационный анализ днк в плазме для детектирования рака
EA048297B1 (ru) Мутационный анализ днк в плазме для детектирования рака